Nutra RX Arnica Pain and Healing
- Manufacturer
- Feelgood Health | W. Last
- Effective date
- 2010-09-22
- Label type
- HUMAN OTC DRUG LABEL
- Version
- 2
- Source
- full-release
- Hydrated at
- 2026-06-01 02:02:38
Label at a glance#
Contacts and useful links#
Label contents#
Full prescribing information#
OTC - PURPOSE SECTION
Reduces swelling and bruising
INDICATIONS & USAGE SECTION
Indications: Homeopathic remedy temporarily relieves discomfort, swelling and bruising after surgery or injury.
DOSAGE & ADMINISTRATION SECTION
Directions: Chew 2 tablets every 30 minutes for up to 10 doses. Thereafter, chew 2 tablets 3 times daily.
GENERAL PRECAUTIONS SECTION
Warning: Do not use 2 weeks prior to surgery or childbirth. If symptoms persist or worsen, a health care professional should be consulted. Keep this and all medicines from the reach of children.
OTC - ACTIVE INGREDIENT SECTION
Ingredients: Each dose contains equal parts of Bellis (3X) (HPUS), Symphytum (3X) (HPUS), Arnica (6X ) (HPUS), Mag phos (6X) (HPUS), Chamomilla (6X) (HPUS)
INACTIVE INGREDIENT SECTION
Lactose (inactive ingredient).
PREGNANCY SECTION
If pregnant or breastfeeding, ask a health professional before use.
WARNINGS SECTION
Contains no gluten, artificial flavors, colors or preservatives. Safe for all ages and during pregnancy.
INFORMATION FOR PATIENTS SECTION
All NutraRx products are especially formulated by experts in the field of natural health and are manufactured according to the highest pharmaceutical standards for maximum safety and effectiveness.
NutraRx
6531 Park of Commerce
Blvd., Suite 160
Boca Raton, FL 33487
Phone: +1.877.289.1235
International: +1.561.999.8857
Made in South Africa
The letters HPUS indicate that the component(s) in this product is (are) officially monographed in the Homeopathic Pharmacopoeia of the United States (HPUS).
PACKAGE LABEL.PRINCIPAL DISPLAY PANEL
OTC - KEEP OUT OF REACH OF CHILDREN SECTION
Keep this and all medicines from the reach of children.
DailyMed Product Concepts#
FDA-Initiated Inactive NDC Indexing#
| NDC | Effective | Action | Document | Indexing SPL | Related label |
|---|---|---|---|---|---|
| 68647-192-10 | 2019-10-21 | C162847 | 48780-1 | 956f9ecf-c49e-621f-e053-dbdaa90a74ad | NUTRARX ARNICA AND PAIN |
DailyMed Package Descriptions#
| Package NDC | Product | Description | Form | Quantity | Strength | SPL version |
|---|---|---|---|---|---|---|
| 68647-192-10 | Nutra RX Arnica Pain and Healing | 125 in 1 BOTTLE, GLASS | TABLET | 125 | 2 |
DailyMed Dashboard NDC Coverage#
DailyMed Socrata Ingredients#
| Ingredient | Type | UNII | SPL version | Uploaded |
|---|---|---|---|---|
| ARNICA MONTANA | ACTIVE INGREDIENT | O80TY208ZW | 2 | |
| BELLIS PERENNIS | ACTIVE INGREDIENT | 2HU33I03UY | 2 | |
| COMFREY ROOT | ACTIVE INGREDIENT | M9VVZ08EKQ | 2 | |
| MAGNESIUM PHOSPHATE | ACTIVE INGREDIENT | 453COF7817 | 2 | |
| MATRICARIA RECUTITA | ACTIVE INGREDIENT | G0R4UBI2ZZ | 2 | |
| ARNICA MONTANA | ACTIVE MOIETY | O80TY208ZW | 2 | |
| BELLIS PERENNIS | ACTIVE MOIETY | 2HU33I03UY | 2 | |
| COMFREY ROOT | ACTIVE MOIETY | M9VVZ08EKQ | 2 | |
| MAGNESIUM CATION | ACTIVE MOIETY | T6V3LHY838 | 2 | |
| MATRICARIA RECUTITA | ACTIVE MOIETY | G0R4UBI2ZZ | 2 | |
| LACTOSE | INACTIVE INGREDIENT | J2B2A4N98G | 2 |
Products#
Every source-derived product name is available through these pages.
- Nutra RX Arnica Pain and Healing
- Bellis, Symphytum, Arnica , Mag phos, Chamomilla
- BELLIS PERENNIS
- COMFREY ROOT
- ARNICA MONTANA
- MAGNESIUM PHOSPHATE
- MAGNESIUM CATION
- MATRICARIA RECUTITA
- LACTOSE
NDC Codes#
| Product NDC | Package NDC |
|---|---|
| 68647-192 | 68647-192-10 |
Ingredients#
Every source-derived ingredient row is available through these pages.
| Name | UNII | Kind |
|---|---|---|
| BELLIS PERENNIS | 2HU33I03UY | ACTIB |
| COMFREY ROOT | M9VVZ08EKQ | ACTIB |
| ARNICA MONTANA | O80TY208ZW | ACTIB |
| MAGNESIUM PHOSPHATE | 453COF7817 | ACTIB |
| MATRICARIA RECUTITA | G0R4UBI2ZZ | ACTIB |
| LACTOSE | J2B2A4N98G | IACT |
Source Document#
Inactive ingredient matches#
Inactive Ingredient Database values describe FDA-listed use contexts. The match method and ambiguity count are shown because ingredient names, routes, and dosage forms are not always unique. Browse recovered IID releases and source provenance.
| DailyMed ingredient | IID ingredient | UNII | Dosage form / route | Potency | Maximum daily exposure | Match |
|---|---|---|---|---|---|---|
| LACTOSE | LACTOSE | J2B2A4N98G | INJECTION, POWDER, FOR SOLUTION / INTRAMUSCULAR | 133 mg | ||
| LACTOSE | LACTOSE | J2B2A4N98G | CAPSULE, DELAYED RELEASE / ORAL | 231.84 mg | ||
| LACTOSE | LACTOSE | J2B2A4N98G | TABLET, EFFERVESCENT / ORAL | 96.5 mg | ||
| LACTOSE | LACTOSE | J2B2A4N98G | TABLET, FILM COATED / ORAL | 590 mg | ||
| LACTOSE | LACTOSE | J2B2A4N98G | SOLUTION / RECTAL | 8 %w/v | ||
| LACTOSE | LACTOSE | J2B2A4N98G | OINTMENT / TOPICAL | NA | ||
| LACTOSE | LACTOSE | J2B2A4N98G | POWDER / VAGINAL | 430 mg | ||
| LACTOSE | LACTOSE | J2B2A4N98G | POWDER / RESPIRATORY (INHALATION) | 90 mg | ||
| LACTOSE | LACTOSE | J2B2A4N98G | SOLUTION / ORAL | 1682 mg/15ml | ||
| LACTOSE | LACTOSE | J2B2A4N98G | CAPSULE, EXTENDED RELEASE / ORAL | 120 mg | ||
| LACTOSE | LACTOSE | J2B2A4N98G | TABLET, SUGAR COATED / ORAL | NA | ||
| LACTOSE | LACTOSE | J2B2A4N98G | TABLET / RECTAL | 20 mg | ||
| LACTOSE | LACTOSE | J2B2A4N98G | CAPSULE / ORAL | 530 mg | ||
| LACTOSE | LACTOSE | J2B2A4N98G | FILM, EXTENDED RELEASE / TRANSDERMAL | 675 mg | ||
| LACTOSE | LACTOSE | J2B2A4N98G | INJECTION, SOLUTION / INTRAVENOUS | 0.45 %w/v | ||
| LACTOSE | LACTOSE | J2B2A4N98G | TABLET, DELAYED RELEASE / ORAL | 160 mg | ||
| LACTOSE | LACTOSE | J2B2A4N98G | CONCENTRATE / ORAL | NA | ||
| LACTOSE | LACTOSE | J2B2A4N98G | INJECTION, POWDER, FOR SOLUTION / INTRAVENOUS | 133 mg | ||
| LACTOSE | LACTOSE | J2B2A4N98G | SUPPOSITORY / VAGINAL | NA | ||
| LACTOSE | LACTOSE | J2B2A4N98G | CAPSULE, COATED, EXTENDED RELEASE / ORAL | NA | ||
| LACTOSE | LACTOSE | J2B2A4N98G | CREAM / VAGINAL | 3 %w/w | ||
| LACTOSE | LACTOSE | J2B2A4N98G | TABLET, FILM COATED, EXTENDED RELEASE / ORAL | 620 mg | ||
| LACTOSE | LACTOSE | J2B2A4N98G | INJECTION / INTRAVENOUS | 203.5 mg | ||
| LACTOSE | LACTOSE | J2B2A4N98G | INJECTION, POWDER, FOR SOLUTION / SUBCUTANEOUS | 133 mg | ||
| LACTOSE | LACTOSE | J2B2A4N98G | CAPSULE, COATED PELLETS / ORAL | 135.2 mg | ||
| LACTOSE | LACTOSE | J2B2A4N98G | TABLET, EXTENDED RELEASE / ORAL | 400 mg | ||
| LACTOSE | LACTOSE | J2B2A4N98G | CAPSULE / RESPIRATORY (INHALATION) | 44.4 mg | ||
| LACTOSE | LACTOSE | J2B2A4N98G | GRANULE, FOR SUSPENSION / ORAL | 512.5 mg/5ml | ||
| LACTOSE | LACTOSE | J2B2A4N98G | TABLET / ORAL | 2500 mg | ||
| LACTOSE | LACTOSE | J2B2A4N98G | POWDER, FOR SOLUTION / ORAL | NA | ||
| LACTOSE | LACTOSE | J2B2A4N98G | TABLET, COATED / ORAL | 332.05 mg | ||
| LACTOSE | LACTOSE | J2B2A4N98G | INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION / INTRACAVITARY | 193.8 mg | ||
| LACTOSE | LACTOSE | J2B2A4N98G | INJECTION / INTRAMUSCULAR | 203.5 mg | ||
| LACTOSE | LACTOSE | J2B2A4N98G | TABLET / SUBLINGUAL | 352 mg | ||
| LACTOSE | LACTOSE | J2B2A4N98G | TABLET, CHEWABLE / ORAL | 1412 mg | ||
| LACTOSE | LACTOSE | J2B2A4N98G | TABLET / BUCCAL | 296.7 mg |
openFDA label cross-check#
OpenFDA label data provides additional search and identifier links. DailyMed’s Structured Product Label is the canonical label on FDA.report. Matching records are deduplicated before they are shown below.
| Brand | Generic | Manufacturer | SPL set ID | Effective date | Available safety fields | Join |
|---|---|---|---|---|---|---|
| 811fee6a-17fa-484a-b4c9-0c5f96bf3560 | dad0ad76-98ef-4b67-a841-bd308b737350 | 2010-09-22 | Warnings | 811fee6a-17fa-484a-b4c9-0c5f96bf3560 dad0ad76-98ef-4b67-a841-bd308b737350 |
Reported adverse events (FAERS/openFDA)#
Adverse event summaries are temporarily unavailable. Other product information remains available.
